OXFORD, UK--Oxford Molecular Group here has entered into an agreement to invest as much as £5 million in Cambridge Drug Discovery, a new company that will specialize in providing advanced high-throughput screening services. Through a close collaboration with Cambridge, Oxford will offer an integrated drug design, synthesis, and screening service. Following the investment, Cambridge's services will be sold through Oxford's sales network.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.